Century Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Century Therapeutics yıllık ortalama 8.3% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 36.2% annual. Gelirler yılda ortalama 74.4% oranında büyüyor .

Anahtar bilgiler

8.32%

Kazanç büyüme oranı

45.61%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.04%
Gelir büyüme oranı	74.44%
Özkaynak getirisi	-40.71%
Net Marj	n/a
Son Kazanç Güncellemesi	31 Mar 2026

Yakın geçmiş performans güncellemeleri

Recent updates

Analiz Makalesi • Dec 17

There's No Escaping Century Therapeutics, Inc.'s (NASDAQ:IPSC) Muted Revenues Despite A 32% Share Price Rise

Century Therapeutics, Inc. ( NASDAQ:IPSC ) shareholders have had their patience rewarded with a 32% share price jump in...

Analiz Makalesi • Nov 30

We're Keeping An Eye On Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analiz Makalesi • Oct 08

There Is A Reason Century Therapeutics, Inc.'s (NASDAQ:IPSC) Price Is Undemanding

Century Therapeutics, Inc.'s ( NASDAQ:IPSC ) price-to-sales (or "P/S") ratio of 0.4x might make it look like a strong...

Seeking Alpha • Jun 20

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Summary Positive poster presentation results were released at ASCO 2024 from the phase 1 ELiPSE-1 study, which used CNTY-101 for the treatment of patients with relapsed/refractory CD19-positive non-Hodgkin lymphoma patients. The global non-Hodgkin Lymphoma market is expected to surge to $11 billion by 2029. Initiation of phase 1 CALiPSO-1 study, using CNTY-101 for patients with systemic lupus erythematosus, is expected in the 1st half of 2024; Data from this study is to be released 2nd half of 2024. A highly important thing about this company would be the Allo-Evasion technology incorporated into the iPSC-derived cell therapies, which not only improves the safety of patients but could mean improved responses. Read the full article on Seeking Alpha

Analiz Makalesi • Mar 06

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Seeking Alpha • Feb 01

Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy

Summary Century Therapeutics is a biotech focused on developing engineered natural killer cells for cancer and rheumatologic conditions. Their first clinical product, CNTY-101, showed promising early data with a patient experiencing tumor shrinkage and a complete clinical response. However, Century Therapeutics has a limited cash position and needs to prove the efficacy of their therapies before being considered a confident investment. Read the full article on Seeking Alpha

Analiz Makalesi • Oct 23

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Aug 25

Century Therapeutics receives IND clearance for allogeneic cell therapy candidate

Century Therapeutics (NASDAQ:IPSC) will begin a phase 1 study of its allogeneic cell therapy CNTY-101 by the end of the year after receiving Investigational New Drug clearance from the US FDA. CNTY-101 is under investigation for relapsed or refractory CD19 positive B-cell malignancies. In the ELiPSE-1 study, all patients will receive an initial standard dose of conditioning chemotherapy. Schedule A consists of a single-dose escalation of CNTY-101 and subcutaneous IL-2. Schedule B will evaluate a three-dose schedule per cycle of CNTY-101. CNTY-101 is derived from a clonal induced pluripotent stem cell (iPSC) master cell bank that yields homogeneous product. Seeking Alpha's Quant Rating views Century (IPSC) as a hold with strong grades for profitability and momentum.

Gelir ve Gider Dağılımı

Century Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqCM:IPSC Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
31 Mar 26	0	-108	28	0
31 Dec 25	109	-10	29	0
30 Sep 25	113	-26	31	0
30 Jun 25	114	-23	33	0
31 Mar 25	115	-22	34	0
31 Dec 24	7	-127	35	0
30 Sep 24	3	-130	35	0
30 Jun 24	2	-131	35	0
31 Mar 24	1	-133	35	0
31 Dec 23	2	-137	35	0
30 Sep 23	2	-129	34	0
30 Jun 23	5	-127	33	0
31 Mar 23	6	-125	33	0
31 Dec 22	5	-131	32	0
30 Sep 22	5	-127	30	0
30 Jun 22	2	-123	28	0
31 Mar 22	1	-115	24	0
31 Dec 21	0	-96	19	0
30 Sep 21	0	-83	16	12
30 Jun 21	0	-70	12	23
31 Mar 21	0	-62	10	32
31 Dec 20	0	-54	9	40

Kaliteli Kazançlar: IPSC şu anda kârlı değil.

Büyüyen Kar Marjı: IPSC şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: IPSC kârlı değildir, ancak son 5 yılda zararlarını yılda 8.3% oranında azaltmıştır.

Büyüme Hızlandırma: IPSC 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: IPSC kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 54.5% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: IPSC hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -40.71% ) sahiptir.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/07/08 01:37
Gün Sonu Hisse Fiyatı	2026/07/08 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Century Therapeutics, Inc. 10 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Geoffrey Meacham	BofA Global Research
Chen Yang	BofA Global Research
William Maughan	Canaccord Genuity

Century Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Full year 2025 earnings: EPS exceeds analyst expectations

Third quarter 2025 earnings released: US$0.40 loss per share (vs US$0.37 loss in 3Q 2024)

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Recent updates

Century Therapeutics Presents New Preclinical Data for CNTY-813 Islet Replacement Therapy At ADA 2026

New major risk - Financial position

Price target increased by 22% to US$3.67

Century Therapeutics, Inc., Annual General Meeting, Jun 11, 2026

Full year 2025 earnings: EPS exceeds analyst expectations

Century Therapeutics, Inc. announced that it has received $134.997458 million in funding from a group of investors

New major risk - Shareholder dilution

Century Therapeutics, Inc. Announces Resignation of Carlo Rizzuto as Director., Effective December 18, 2025

New minor risk - Share price stability

There's No Escaping Century Therapeutics, Inc.'s (NASDAQ:IPSC) Muted Revenues Despite A 32% Share Price Rise

Century Therapeutics, Inc. Announces Board and Committee Appointments

We're Keeping An Eye On Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

Third quarter 2025 earnings released: US$0.40 loss per share (vs US$0.37 loss in 3Q 2024)

Century Therapeutics, Inc. Announces New Beta Islet Program for Type 1 Diabetes

There Is A Reason Century Therapeutics, Inc.'s (NASDAQ:IPSC) Price Is Undemanding

Price target decreased by 11% to US$4.25

Nasdaq Grants Century Therapeutics an Additional 180 Calendar Day Period, or Until February 23, 2026, to Regain Compliance with the Bid Price Rule

Century Therapeutics, Inc. Announces Board and Committee Changes, Effective August 14, 2025

Century Therapeutics, Inc. Announces Departure of Morgan Conn, Ph.D. as the Chief Financial Officer, Effective July 11, 2025

Consensus revenue estimates increase by 115%

Price target decreased by 8.3% to US$4.40

New major risk - Financial position

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Century Therapeutics, Inc., Annual General Meeting, Jun 12, 2025

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 2,092%

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Century Therapeutics, Inc. Provides Business Update for Clinical Pipeline for CNTY-101

Century Therapeutics Receives A Notification Letter from the Nasdaq Stock Market Regarding Listing Rule 5450(a)(1)

Price target increased by 8.0% to US$9.00

Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-Derived iNK Cell Therapy Cnty-101 in B-Cell Mediated Autoimmune Diseases

New major risk - Shareholder dilution

New minor risk - Market cap size

Consensus revenue estimates increase by 23%

Price target decreased by 11% to US$10.40

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Market cap size

Century Therapeutics, Inc. Appoints Chad Cowan as Chief Scientific Officer, Effective October 1, 2024

Century Therapeutics, Inc. Appoints Morgan Conn as Chief Financial Officer, Effective October 14, 2024

Price target decreased by 7.1% to US$11.33

Consensus revenue estimates increase by 24%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Century Therapeutics Presents Interim Results from Phase 1 Elipse-1 Study At Asco 2024 Annual Meeting

Price target decreased by 18% to US$12.20

Consensus revenue estimates increase by 77%

Century Therapeutics Presents Preclinical Data Highlighting Advances in Ipsc Platform Technology and Programs At 2024 Asgct Annual Meeting

First quarter 2024 earnings released: US$0.45 loss per share (vs US$0.53 loss in 1Q 2023)

Century Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

Century Therapeutics, Inc. announced that it expects to receive $59.999982 million in funding from a group of investors

Century Therapeutics, Inc. (NasdaqGS:IPSC) agreed to acquire Clade Therapeutics, Inc. from Syncona Limited (LSE:SYNC) for $45 million.

Consensus revenue estimates decrease by 86%, EPS upgraded

Full year 2023 earnings released: US$2.30 loss per share (vs US$2.27 loss in FY 2022)

COO & Head of Early Development notifies of intention to sell stock

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy

Century Therapeutics, Inc. Announces CFO Changes

Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for A Multi-Dosing Strategy for Car iNK Enabled by Allo-Evasion Edits

Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

New minor risk - Share price stability

Consensus revenue estimates fall by 32%

Century Therapeutics, Inc. Announces Chief Executive Officer Changes

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

New major risk - Financial position

New minor risk - Market cap size

Consensus revenue estimates increase by 20%

Price target decreased by 19% to US$14.00

Consensus revenue estimates decrease by 48%, EPS upgraded

New major risk - Financial position